Klinikum Frankfurt (Oder) GmbH

Running trials

• Active, not recruiting

  A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheimer’s Disease (AD)

  2023-506183-13-00· Phase 2· Source

• Recruiting

  A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

  NCT06149286· Phase 3· Source

• Recruiting

  Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

  NCT05820841· Phase 3· Source

• Active, not recruiting

  Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

  NCT04083339· Phase 3· Source

• Active, not recruiting

  Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

  NCT03617731· Phase 3· Source

• Recruiting

  Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

  NCT03188874· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Hodgkin lymphoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressive B-cell Non-Hodgkin Lymphoma.

  NCT06230224· Phase 3· Source

• Completed

  Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

  NCT02242942· Phase 3· Source